Jenne Kyle 4

What Happened
Jenne Kyle, EVP and Chief Global Product Strategy Officer at Ionis Pharmaceuticals (IONS), exercised options to acquire a total of 37,277 shares (32,602 @ $46.10 and 4,675 @ $34.69) on March 10, 2026, and sold the same 37,277 shares that day in open-market transactions (21,191 @ $75.50 and 16,086 @ $76.30). Gross proceeds from the sales were about $2,827,325; the exercise payments totaled $1,665,128, implying roughly $1.16M pre-tax difference between sales proceeds and option exercise cost. The filing also shows the corresponding derivative instruments were disposed (reported at $0.00), indicating conversion of those instruments into the shares.

Key Details

• Transaction date: 2026-03-10 (Form 4 filed 2026-03-11 — timely; Form 4s are due within 2 business days)
• Acquired via exercise (Code M): 32,602 shares @ $46.10 ($1,502,952) and 4,675 shares @ $34.69 ($162,176) — total acquired 37,277 shares.
• Sold (Code S): 21,191 shares @ weighted avg $75.50 ($1,599,963) and 16,086 shares @ weighted avg $76.30 ($1,227,362) — total sold 37,277 shares; total sales ≈ $2,827,325.
• Footnotes: sales were made under a Rule 10b5-1 trading plan adopted Dec 8, 2025; reported sale prices are weighted averages with per-trade price ranges provided in the filing.
• Shares owned after transaction: not specified in the excerpt provided.

Context
This is a common “exercise-and-sell” (cashless) pattern: options were exercised and the resulting shares were immediately sold the same day. Sales executed under a 10b5-1 plan indicate the trades were prearranged rather than ad hoc. These transactions are routine insider liquidity events and should be viewed as such; they do not necessarily signal a change in the insider’s view of the company.